Pub Date : 2025-03-01DOI: 10.1016/j.arteri.2024.08.004
Sebastián Mas-Fontao , Nieves Tarín , Carmen Cristóbal , Manuel Soto-Catalán , Ana Pello , Alvaro Aceña , Jairo Lumpuy-Castillo , Carmen Garces , Carmen Gomez-Guerrero , Carlos Gutiérrez-Landaluce , Luis M. Blanco-Colio , José Luis Martín-Ventura , Ana Huelmos , Joaquín Alonso , Lorenzo López Bescós , Juan A. Moreno , Ignacio Mahíllo-Fernández , Óscar Lorenzo , María Luisa González-Casaus , Jesús Egido , José Tuñón
Objectives
To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.
Methods
A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).
Results
There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (P<.001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81-6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; P=.035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.
Conclusions
Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.
{"title":"Los niveles plasmáticos elevados de TNF-R1 predicen el desarrollo de eventos isquémicos agudos en pacientes coronarios con diabetes","authors":"Sebastián Mas-Fontao , Nieves Tarín , Carmen Cristóbal , Manuel Soto-Catalán , Ana Pello , Alvaro Aceña , Jairo Lumpuy-Castillo , Carmen Garces , Carmen Gomez-Guerrero , Carlos Gutiérrez-Landaluce , Luis M. Blanco-Colio , José Luis Martín-Ventura , Ana Huelmos , Joaquín Alonso , Lorenzo López Bescós , Juan A. Moreno , Ignacio Mahíllo-Fernández , Óscar Lorenzo , María Luisa González-Casaus , Jesús Egido , José Tuñón","doi":"10.1016/j.arteri.2024.08.004","DOIUrl":"10.1016/j.arteri.2024.08.004","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.</div></div><div><h3>Methods</h3><div>A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).</div></div><div><h3>Results</h3><div>There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (<em>P</em><.001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81-6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; <em>P</em>=.035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.</div></div><div><h3>Conclusions</h3><div>Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100735"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.arteri.2024.06.002
Elena Vilalta Doñate , Francisca García Fernández , Salvador Martínez Meléndez , Consuelo Castillo Castillo , Pablo Salas Medina , Isabel Almodóvar Fernández
Introduction
Adherence to the Mediterranean diet (Dietmed) exerts protective effects on cardiovascular disease (CVD). In the Lower Extremity Peripheral Arterial Disease (PAD) there are fewer studies that analyze these data.
Objective
To determine adherence to Dietmed and dietary habits in patients with PAD, according to a history of CVD (coronary and/or cerebral ischaemic pathology) and according to the ankle-brachial index (ABI ≥ or <0,5).
Material and methods
Cross-sectional analytical study carried out in a tertiary hospital. The sample was collected consecutively. Sociodemographic and clinical history, ankle-brachial index (ABI) and a 14-point Dietmed adherence dietary questionnaire were included. The analysis of categorical variables was carried out using the Pearson's Chi-Square test, the T-Student's statistic test for independent samples was used for parametric variables and the U. Mann-Whitney test for non-parametric variables.
Results
Of the 97 patients, 87,6% had low adherence to Dietmed, with no differences according to the severity of PAD. However, when we analysed the data according to whether or not they had a history of CVD, we observed a high adherence to some items included in Dietmed, specifically, in the CVD group, the consumption of lean meat (95,5% vs 64%; P=.004). In addition, we observed a significant difference in the consumption in the group without a history of CVD (32% vs 9,1%; P=.033).
Conclusion
In our population, patients with PAD, regardless of the stage of the disease and whether they had associated coronary or cerebral ischaemic pathology, had low adherence to Dietmed. Therefore, it is important to implement nutritional education programmes in patients with PAD in all stages, as well as in those patients who have already suffered a vascular event, so that they maintain adherence to healthy dietary habits in the long term.
导言：坚持地中海饮食（Dietmed）对心血管疾病（CVD）具有保护作用。在下肢外周动脉疾病（PAD）方面，对这些数据进行分析的研究较少：根据心血管疾病病史（冠心病和/或脑缺血病）和踝肱指数（ABI ≥ 或 材料和方法：在一家三级医院进行的横断面分析研究。样本连续采集。研究纳入了社会人口学和临床病史、踝肱指数（ABI）和 14 点 Dietmed 饮食依从性问卷。对分类变量的分析采用皮尔逊秩方检验，对参数变量采用独立样本 T-Student 统计检验，对非参数变量采用 U. Mann-Whitney 检验：在 97 名患者中，87.6% 的患者对饮食治疗的依从性较低，与 PAD 的严重程度无关。然而，当我们根据患者是否有心血管疾病病史对数据进行分析时，我们发现他们对饮食医学中某些项目的依从性较高，特别是在心血管疾病组中，瘦肉的摄入量较高（95.5% 对 64%；P=.004）。此外，我们还观察到无心血管疾病史组的食用量有显著差异（32% vs 9.1%；P=.033）：结论：在我们的研究人群中，PAD 患者无论处于哪个阶段，也无论是否伴有冠状动脉或脑缺血病变，对饮食治疗的依从性都很低。因此，对各阶段的 PAD 患者以及已发生血管事件的患者实施营养教育计划非常重要，这样他们才能长期坚持健康的饮食习惯。
{"title":"Hábitos nutricionales en los pacientes con enfermedad arterial periférica: adherencia a la dieta mediterránea","authors":"Elena Vilalta Doñate , Francisca García Fernández , Salvador Martínez Meléndez , Consuelo Castillo Castillo , Pablo Salas Medina , Isabel Almodóvar Fernández","doi":"10.1016/j.arteri.2024.06.002","DOIUrl":"10.1016/j.arteri.2024.06.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Adherence to the Mediterranean diet (Dietmed) exerts protective effects on cardiovascular disease (CVD). In the Lower Extremity Peripheral Arterial Disease (PAD) there are fewer studies that analyze these data.</div></div><div><h3>Objective</h3><div>To determine adherence to Dietmed and dietary habits in patients with PAD, according to a history of CVD (coronary and/or cerebral ischaemic pathology) and according to the ankle-brachial index (ABI ≥ or <0,5).</div></div><div><h3>Material and methods</h3><div>Cross-sectional analytical study carried out in a tertiary hospital. The sample was collected consecutively. Sociodemographic and clinical history, ankle-brachial index (ABI) and a 14-point Dietmed adherence dietary questionnaire were included. The analysis of categorical variables was carried out using the Pearson's Chi-Square test, the T-Student's statistic test for independent samples was used for parametric variables and the U. Mann-Whitney test for non-parametric variables.</div></div><div><h3>Results</h3><div>Of the 97 patients, 87,6% had low adherence to Dietmed, with no differences according to the severity of PAD. However, when we analysed the data according to whether or not they had a history of CVD, we observed a high adherence to some items included in Dietmed, specifically, in the CVD group, the consumption of lean meat (95,5% vs 64%; <em>P</em>=.004). In addition, we observed a significant difference in the consumption in the group without a history of CVD (32% vs 9,1%; <em>P</em>=.033).</div></div><div><h3>Conclusion</h3><div>In our population, patients with PAD, regardless of the stage of the disease and whether they had associated coronary or cerebral ischaemic pathology, had low adherence to Dietmed. Therefore, it is important to implement nutritional education programmes in patients with PAD in all stages, as well as in those patients who have already suffered a vascular event, so that they maintain adherence to healthy dietary habits in the long term.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 2","pages":"Article 100726"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141628054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.10.002
Javier Rodríguez Lega, Ángel González Pinto
{"title":"Evaluación del efecto sobre la trombogenicidad de modificaciones de la superficie en stents de nitinol en un modelo in vitro","authors":"Javier Rodríguez Lega, Ángel González Pinto","doi":"10.1016/j.arteri.2024.10.002","DOIUrl":"10.1016/j.arteri.2024.10.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100742"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.04.002
Oscar Zaragoza-García , Olivia Briceño , José Rafael Villafan-Bernal , Ilse Adriana Gutiérrez-Pérez , Héctor Ugo Rojas-Delgado , Gustavo Adolfo Alonso-Silverio , Antonio Alarcón-Paredes , José Eduardo Navarro-Zarza , Cristina Morales-Martínez , Rubén Rodríguez-García , Iris Paola Guzmán-Guzmán
Aim
The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).
Methods
A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.
Results
Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR) ≥ 0.121 (p = 0.003), total cholesterol/HDL-c ratio > 7% (p = 0.004), LDL-c/HDL-c ratio > 3% (p = 0.035), atherogenic index of plasma > 0.21 (p = 0.004), cardiometabolic index (CMI) ≥ 1.70 (p = 0.005), and high DAS28-ESR (p = 0.004). In multivariate analysis, levels of sCD163 ≥ 1107.3 ng/mL were associated with CHR ≥ 0.121 (OR = 3.43, p = 0.020), CMI ≥ 1.70 (OR = 4.25, p = 0.005), total cholesterol/HDL-c ratio > 7% (OR = 6.63, p = 0.044), as well as with DAS28-ESR > 3.2 (OR = 8.10, p = 0.008). Moreover, levels of sCD163 predicted CHR ≥ 0.121 (AUC = 0.701), cholesterol total/HDL ratio > 7% (AUC = 0.764), and DAS28-ESR > 3.2 (AUC = 0.720).
Conclusion
Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.
目的：可溶性清道夫受体分化抗原163（sCD163）是一种单核细胞/巨噬细胞活化标志物，与普通人群的心血管死亡率有关。本研究旨在评估类风湿关节炎（RA）患者血清中 sCD163 水平与心血管风险指标之间的关系：方法：对 80 名确诊为 RA 的女性进行了横断面研究。方法：我们对 80 名确诊为 RA 的女性进行了横断面研究，并使用血脂概况、代谢综合征和 QRISK3 计算器确定了心血管风险。为了评估 RA 的活动性，我们评估了 DAS28 和红细胞沉降率（DAS28-ESR）。血清中 sCD163 的水平采用 ELISA 方法测定。我们使用逻辑回归模型和接收器操作特征曲线（ROC）评估了sCD163与RA患者心血管风险的相关性和预测价值：结果：高敏感蛋白 C 反应与高密度脂蛋白胆固醇比值（CHR）≥0.121（P=0.003）、总胆固醇/高密度脂蛋白胆固醇比值>7%（P=0.004）、LDL-c/HDL-c 比值＞3%（p=0.035）、血浆致动脉粥样硬化指数＞0.21（p=0.004）、心脏代谢指数（CMI）≥1.70（p=0.005）、DAS28-ESR 偏高（p=0.004）。在多变量分析中，sCD163水平≥1107.3ng/mL与CHR≥0.121（OR=3.43，p=0.020）、CMI≥1.70（OR=4.25，p=0.005）、总胆固醇/HDL-c比值>7%（OR=6.63，p=0.044）以及DAS28-ESR>3.2（OR=8.10，p=0.008）相关。此外，sCD163水平可预测CHR≥0.121（AUC=0.701）、胆固醇总/高密度脂蛋白比率>7%（AUC=0.764）和DAS28-ESR>3.2（AUC=0.720）：结论：血清sCD163水平可被视为RA心血管风险和临床活动的替代指标。
{"title":"Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers","authors":"Oscar Zaragoza-García , Olivia Briceño , José Rafael Villafan-Bernal , Ilse Adriana Gutiérrez-Pérez , Héctor Ugo Rojas-Delgado , Gustavo Adolfo Alonso-Silverio , Antonio Alarcón-Paredes , José Eduardo Navarro-Zarza , Cristina Morales-Martínez , Rubén Rodríguez-García , Iris Paola Guzmán-Guzmán","doi":"10.1016/j.arteri.2024.04.002","DOIUrl":"10.1016/j.arteri.2024.04.002","url":null,"abstract":"<div><h3>Aim</h3><div>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163<span> were determined by the ELISA<span> method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</span></span></div></div><div><h3>Results</h3><div>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)<!--> <!-->≥<!--> <!-->0.121 (<em>p</em> <!-->=<!--> <!-->0.003), total cholesterol/HDL-c ratio<!--> <!-->><!--> <!-->7% (<em>p</em> <!-->=<!--> <!-->0.004), LDL-c/HDL-c ratio<!--> <!-->><!--> <!-->3% (<em>p</em> <!-->=<!--> <!-->0.035), atherogenic index of plasma<!--> <!-->><!--> <!-->0.21 (<em>p</em> <!-->=<!--> <!-->0.004), cardiometabolic index (CMI)<!--> <!-->≥<!--> <!-->1.70 (<em>p</em> <!-->=<!--> <!-->0.005), and high DAS28-ESR (<em>p</em> <!-->=<!--> <!-->0.004). In multivariate analysis, levels of sCD163<!--> <!-->≥<!--> <!-->1107.3<!--> <!-->ng/mL were associated with CHR<!--> <!-->≥<!--> <!-->0.121 (OR<!--> <!-->=<!--> <!-->3.43, <em>p</em> <!-->=<!--> <!-->0.020), CMI<!--> <!-->≥<!--> <!-->1.70 (OR<!--> <!-->=<!--> <!-->4.25, <em>p</em> <!-->=<!--> <!-->0.005), total cholesterol/HDL-c ratio<!--> <!-->><!--> <!-->7% (OR<!--> <!-->=<!--> <!-->6.63, <em>p</em> <!-->=<!--> <!-->0.044), as well as with DAS28-ESR<!--> <!-->><!--> <!-->3.2 (OR<!--> <!-->=<!--> <!-->8.10, <em>p</em> <!-->=<!--> <!-->0.008). Moreover, levels of sCD163 predicted CHR<!--> <!-->≥<!--> <!-->0.121 (AUC<!--> <!-->=<!--> <!-->0.701), cholesterol total/HDL ratio<!--> <!-->><!--> <!-->7% (AUC<!--> <!-->=<!--> <!-->0.764), and DAS28-ESR<!--> <!-->><!--> <!-->3.2 (AUC<!--> <!-->=<!--> <!-->0.720).</div></div><div><h3>Conclusion</h3><div>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100721"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140904932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.05.001
Vicente Pallarés-Carratalá , Antonio Ruiz-García , Adalberto Serrano-Cumplido , Antonio Segura Fragoso , Verónica Fernández-Pascual , Beatriz Sánchez-Sánchez , María Inmaculada Cervera-Pérez , Francisco Javier Alonso-Moreno , Ezequiel Arranz-Martínez , Alfonso Barquilla-García , Daniel Rey-Aldana , José Polo García , Sergio Cinza-Sanjurjo , on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation
Introduction
Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.
Objectives
To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.
Methods
This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's d was used to assess the standardised difference in means.
Results
Six hundred and five patients with T2D were assessed (mean age 63.5 [SD ± 8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8 mmHg), higher body weight (BW) (3.7 kg), and higher glycated haemoglobin A1c (HbA1c) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA1c > 8%) at recruitment, 54.9% had good glycaemic control (HbA1c < 7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).
Conclusions
Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA1c control. Future research is necessary to explain the causes of these differences in cardiometabolic control.
{"title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","authors":"Vicente Pallarés-Carratalá , Antonio Ruiz-García , Adalberto Serrano-Cumplido , Antonio Segura Fragoso , Verónica Fernández-Pascual , Beatriz Sánchez-Sánchez , María Inmaculada Cervera-Pérez , Francisco Javier Alonso-Moreno , Ezequiel Arranz-Martínez , Alfonso Barquilla-García , Daniel Rey-Aldana , José Polo García , Sergio Cinza-Sanjurjo , on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation","doi":"10.1016/j.arteri.2024.05.001","DOIUrl":"10.1016/j.arteri.2024.05.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.</div></div><div><h3>Objectives</h3><div>To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.</div></div><div><h3>Methods</h3><div>This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's <em>d</em> was used to assess the standardised difference in means.</div></div><div><h3>Results</h3><div>Six hundred and five patients with T2D were assessed (mean age 63.5 [SD<!--> <!-->±<!--> <!-->8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8<!--> <!-->mmHg), higher body weight (BW) (3.7<!--> <!-->kg), and higher glycated haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA<sub>1c</sub> <!-->><!--> <!-->8%) at recruitment, 54.9% had good glycaemic control (HbA<sub>1c</sub> <!--><<!--> <!-->7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).</div></div><div><h3>Conclusions</h3><div>Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA<sub>1c</sub> control. Future research is necessary to explain the causes of these differences in cardiometabolic control.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100724"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2025.500764
Francisco Pérez-Jiménez
{"title":"Las recomendaciones nutricionales: una fácil y difícil tarea para el médico","authors":"Francisco Pérez-Jiménez","doi":"10.1016/j.arteri.2025.500764","DOIUrl":"10.1016/j.arteri.2025.500764","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 500764"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.08.002
Francesco Sbrana, Beatrice Dal Pino
{"title":"When “old” lipid lowering therapies not should be discontinued","authors":"Francesco Sbrana, Beatrice Dal Pino","doi":"10.1016/j.arteri.2024.08.002","DOIUrl":"10.1016/j.arteri.2024.08.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100732"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142298096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.04.004
Kung-Hung Lin , Nuria Amigo , Pablo Ortiz , Cristina Alonso , Alexander V. Smolensky , Deven Parmar , Naga P. Chalasani , Samer Gawrieh
Background and aims
Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.
Methods
We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.
Results
The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.
Conclusion
Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.
背景和目的：全面评估药物治疗对影响心血管疾病（CVD）风险的致动脉粥样硬化参数（AP）的影响具有挑战性，因为调节心血管疾病风险的大量参数之间存在相互作用：方法：我们开发了一种说明性工具--动脉粥样硬化轮廓（AC），它结合了加权的主要血脂、脂质和糖蛋白参数，可方便地说明药物治疗后这些参数的整体变化。我们在 EVIDENCES IV 研究中展示了 AC 的适用性，以评估代谢相关性脂肪肝（MAFLD）患者在接受沙格列扎治疗后 AP 的变化：结果：沙格列扎和安慰剂组的基线血浆浓度比一般人群的平均值低。经过16周的治疗后，由于极低密度脂蛋白、甘油三酯和糖蛋白的改变，沙格列扎尔组的AC明显改善：通过 AC，我们可以轻松、全面地评估和观察 AP 的变化。接受沙格列扎治疗后，MAFLD 患者的 AC 有所改善。
{"title":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients","authors":"Kung-Hung Lin , Nuria Amigo , Pablo Ortiz , Cristina Alonso , Alexander V. Smolensky , Deven Parmar , Naga P. Chalasani , Samer Gawrieh","doi":"10.1016/j.arteri.2024.04.004","DOIUrl":"10.1016/j.arteri.2024.04.004","url":null,"abstract":"<div><h3>Background and aims</h3><div>Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.</div></div><div><h3>Methods</h3><div>We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.</div></div><div><h3>Results</h3><div>The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.</div></div><div><h3>Conclusion</h3><div>Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100723"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.arteri.2024.10.001
Emilio Ros , Pablo Pérez-Martínez , Ramón Estruch , José López-Miranda , Cristina Soler Ferrer , Javier Delgado-Lista , Francisco Gómez-Delgado , Rosa Solà , Vicente Pascual
{"title":"Documento de recomendaciones de la Sociedad Española de Arteriosclerosis (SEA). La dieta en la prevención cardiovascular. Actualizacion 2024","authors":"Emilio Ros , Pablo Pérez-Martínez , Ramón Estruch , José López-Miranda , Cristina Soler Ferrer , Javier Delgado-Lista , Francisco Gómez-Delgado , Rosa Solà , Vicente Pascual","doi":"10.1016/j.arteri.2024.10.001","DOIUrl":"10.1016/j.arteri.2024.10.001","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 1","pages":"Article 100741"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.arteri.2024.11.001
María José Ariza Corbo , Ovidio Muñiz-Grijalvo , Agustín Blanco Echevarría , J.L. Díaz-Díaz
The development of massive sequencing techniques and guidelines for assessing the pathogenicity of variants are allowing us the identification of new cases of familial chylomicronemia syndrome (FCS) mostly in the LPL gene, less frequently in GPIHBP1 and APOA5, and with even fewer cases in LMF1 and APOC2. From the included studies, it can be deduced that, in cases with multifactorial chylomicronemia syndrome (MCS), both loss-of-function variants and common variants in canonical genes for FCH contribute to the manifestation of this other form of chylomicronemia. Other common and rare variants in other triglyceride metabolism genes have been identified in MCS patients, although their real impact on the development of severe hypertriglyceridemia is unknown. There may be up to 60 genes involved in triglyceride metabolism, so there is still a long way to go to know whether other genes not discussed in this monograph (MLXIPL, PLTP, TRIB1, PPAR alpha or USF1, for example) are genetic determinants of severe hypertriglyceridemia that need to be taken into account.
{"title":"Bases genéticas de las hipertrigliceridemias","authors":"María José Ariza Corbo , Ovidio Muñiz-Grijalvo , Agustín Blanco Echevarría , J.L. Díaz-Díaz","doi":"10.1016/j.arteri.2024.11.001","DOIUrl":"10.1016/j.arteri.2024.11.001","url":null,"abstract":"<div><div>The development of massive sequencing techniques and guidelines for assessing the pathogenicity of variants are allowing us the identification of new cases of familial chylomicronemia syndrome (FCS) mostly in the LPL gene, less frequently in GPIHBP1 and APOA5, and with even fewer cases in LMF1 and APOC2. From the included studies, it can be deduced that, in cases with multifactorial chylomicronemia syndrome (MCS), both loss-of-function variants and common variants in canonical genes for FCH contribute to the manifestation of this other form of chylomicronemia. Other common and rare variants in other triglyceride metabolism genes have been identified in MCS patients, although their real impact on the development of severe hypertriglyceridemia is unknown. There may be up to 60 genes involved in triglyceride metabolism, so there is still a long way to go to know whether other genes not discussed in this monograph (MLXIPL, PLTP, TRIB1, PPAR alpha or USF1, for example) are genetic determinants of severe hypertriglyceridemia that need to be taken into account.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 ","pages":"Pages S3-S12"},"PeriodicalIF":1.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号